Apr 9 2010![NewsGuard 100/100 Score](https://d2jx2rerrg6sh3.cloudfront.net/images/newsguard-100.svg)
XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that researchers from the Mayo Clinic will be presenting data on the use of XOMA's high-affinity antibody to interleukin-1 beta (IL-1 beta), XOMA 052, in myeloma at the 101st Annual Meeting of the American Association of Cancer Research (AACR).
The poster, entitled "A novel humanized anti-IL-1beta antibody is highly effective at inhibiting IL-1 induced IL-6 production in myeloma patients in vitro" will be presented on Monday, April 19 at 2:00 PM Eastern. The abstract upon which the poster is based is now available on the conference Web site: www.aacr.org.